Analyst Price Target is $35.00
▲ +372.33% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Genelux in the last 3 months. The average price target is $35.00, with a high forecast of $40.00 and a low forecast of $30.00. The average price target represents a 372.33% upside from the last price of $7.41.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Genelux. This Buy consensus rating has held steady for over two years.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.